AONC HealthcareBeta data

American Oncology Network, Inc.

$11.50+0.00%

Price as of close on Feb 5, 2026 · Financials updated Nov 4, 2026

Basics

Sector: Healthcare
Industry: Medical Care Facilities
Country: United States
Market cap: 336.4M USD
Enterprise value: 970.3M USD
Full-time employees: 1,914

Overall health

Strength: more profitable than most peersmore profitable than peers
Strength: growing faster than most peersgrowing faster than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.53 vs a peer median of 2.59)higher risk: less liquidity (current ratio 1.53 vs peers 2.59)

Ranks #777 of 1,157 healthcare companies (bottom 33%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
American Oncology Network's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Growing fast, still losing money. Revenue grew faster than 88% of peers, at an operating loss.
Revenue grew faster than 88% of peers, but the business runs at an operating loss (margin -0.9%).

StockQuotient Score

43/ 100▲ 1 since Feb 5 close

Oct 5 42 → Nov 4 43 (+1)

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

0/100

Weak

2/3 inputs reported · Partial data

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-17.8%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-0.6%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-13.3%

Yahoo FinanceOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

86/100

Strong

2/3 inputs reported · Partial data

Why

Stronger than most peers on:

▲ Revenue growth
▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth23.1%

Yahoo Finance · 3 fiscal years to Dec 2024Reported value33% base weight · Z-score 2.05Sector median: 0.0584 · MAD: 0.0840

Revenue growth37.5%

Yahoo Finance · fiscal year to Dec 2024Reported value33% base weight · Z-score 3.23Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

76/100

Moderate▲ 1 since Feb 5 close

3/3 inputs reported · High confidence

Why it changed since the Feb 5, 2026 close: Score 75 → 76

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-0.9%

Yahoo Finance · fiscal year to Dec 2024Reported value33% base weight · Z-score -0.65Sector median: 0.0706 · MAD: 0.1217

Return on assets-2.4%

Yahoo Finance · trailing 12 monthsReported value33% base weight · Z-score -0.75Sector median: 0.0166 · MAD: 0.0537

Return on invested capital70.9%

Yahoo Finance · trailing 12 monthsOutlier capped at sector 5th/95th percentile33% base weight · Z-score 3.81Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin6.8%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-30.2%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Why it changed since the Feb 5, 2026 close: Safety percentile 8 → 9

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Weaker than most peers on:

▼ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.36

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.77Sector median: 0.6250 · MAD: 0.3380

Current ratio1.53×

Yahoo FinanceReported value33% base weight · Z-score -0.76Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about American Oncology Network

Is American Oncology Network getting weaker?: Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is 43/100, up 1 since Oct 28, 2026.
How is American Oncology Network valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -17.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -17.8% vs peers 1.5% (weaker than 100% of peers).
Is American Oncology Network growing?: Yes, faster than most of its peers. Growth scores 86/100 against 1,393 healthcare peers. Revenue growth 37.5% vs a peer median of 6.1% (stronger than 88% of peers).Revenue growth 37.5% vs peers 6.1% (stronger than 88% of peers).
How profitable is American Oncology Network?: More profitable than most of its peers. Profitability scores 76/100 against 1,393 healthcare peers. Return on invested capital 70.9% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 70.9% vs peers 4.7% (stronger than 95% of peers). Operating margin -0.9% vs a peer median of 7.1% (weaker than 68% of peers).Operating margin -0.9% vs peers 7.1% (weaker than 68% of peers).
How risky is American Oncology Network?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.36 vs a peer median of 0.63 (stronger than 73% of peers).Beta 0.36 vs peers 0.63 (stronger than 73% of peers). Current ratio 1.53× vs a peer median of 2.59× (weaker than 73% of peers).Current ratio 1.53× vs peers 2.59× (weaker than 73% of peers). A relative measure, not a bankruptcy probability.

Industry valuation context

Industry: Medical Care Facilities · 27 companies

Valuations in Medical Care Facilities are within their usual range since Jun 2017.

39% of months since Jun 2017 were valued lower than now.
28% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is −61% vs the whole market, against a usual −56%.

Jun 2017Shaded: most expensive fifth of its range2026

Financials

Detailed annual statements come from structured SEC filing data, which most US companies and some foreign filers provide. They aren’t available for this company yet.

AONC price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: more profitable than most peersmore profitable than peers

Strength: growing faster than most peersgrowing faster than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.53 vs a peer median of 2.59)higher risk: less liquidity (current ratio 1.53 vs peers 2.59)

Ranks #777 of 1,157 healthcare companies (bottom 33%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

American Oncology Network's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Growing fast, still losing money. Revenue grew faster than 88% of peers, at an operating loss.

Revenue grew faster than 88% of peers, but the business runs at an operating loss (margin -0.9%).

Questions investors ask about American Oncology Network

Is American Oncology Network getting weaker?

Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is 43/100, up 1 since Oct 28, 2026.

How is American Oncology Network valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -17.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -17.8% vs peers 1.5% (weaker than 100% of peers).

Is American Oncology Network growing?

Yes, faster than most of its peers. Growth scores 86/100 against 1,393 healthcare peers. Revenue growth 37.5% vs a peer median of 6.1% (stronger than 88% of peers).Revenue growth 37.5% vs peers 6.1% (stronger than 88% of peers).

How profitable is American Oncology Network?

More profitable than most of its peers. Profitability scores 76/100 against 1,393 healthcare peers. Return on invested capital 70.9% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 70.9% vs peers 4.7% (stronger than 95% of peers). Operating margin -0.9% vs a peer median of 7.1% (weaker than 68% of peers).Operating margin -0.9% vs peers 7.1% (weaker than 68% of peers).

How risky is American Oncology Network?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.36 vs a peer median of 0.63 (stronger than 73% of peers).Beta 0.36 vs peers 0.63 (stronger than 73% of peers). Current ratio 1.53× vs a peer median of 2.59× (weaker than 73% of peers).Current ratio 1.53× vs peers 2.59× (weaker than 73% of peers). A relative measure, not a bankruptcy probability.